Acute Myocardial Infarction
Conditions
Brief summary
Pneumonia is uncommon high among patients with acute myocardial infarction (AMI), which increases adverse clinical events and prolongs the hospital stay. Inspiratory muscle training (IMT) is able to improve inspiratory muscle strength and prevent pneumonia in patients undergoing cardiac surgery including coronary artery bypass grafting. Thus, the investigators design the study mainly aim to evaluate the 30 days IMT for the change of inspiratory muscle strength, and also to observe its potentially effect on reducing pneumonia, in participants who accepted primary percutaneous coronary intervention (PCI) and at a high risk of pneumonia.
Detailed description
This is a single center, prospective, randomized controlled study. All participants will be followed up until 30 days after randomized.
Interventions
OTHERInspiratory Muscle Training
The inspiratory muscle training (IMT) will be carried out with a load of 30% of maximal inspiratory pressure (MIP) using a threshold inspiratory muscle trainer (c-type, Shengchang medical equipment factory, Yuyao city, China) at the beginning. During the hospital period, the resistance will increase incrementally, based on the rate of perceived exertion scored on the Borg scale (Borg, 1982). If the rate of perceived exertion less than 5, the resistance of the inspiratory threshold trainer will then be increase incrementally by 5%. The load for home-based IMT training will be set as the highest training load in the hospital. All patients will be required in sitting position during training, wearing nose-clips.
Sponsors
Guangdong Provincial People's Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* age ≥ 18 years, patients with AMI undergoing primary PCI, admitted to cardiac intensive care unit and at a high pneumonia risk \[2 or more of the following parameters are regarded as high risk for pneumonia: 1. Age \> 55 years, 2. Diabetes mellitus, 3. Smoking at present, 4. Chronic kidney disease: estimated glomerular filtration rate \< 60 mL/min/1.73m2, 5. Forced expiratory volume in the first second of expiration (FEV1) \< 80% predicted and FEV1/forced vital capacity (FVC) \< 70% predicted\] * be able to understand and agree with informed consent
Exclusion criteria
* a history of cerebrovascular accident * treat with immunosuppressive medication for 30 days before * neuromuscular disorder * cardiovascular instability (such as aortic dissection or unstable hemodynamics) * a history of Coronary Artery Bypass Grafting (CABG) * expected survival is less than 6 months due to noncardiogenic disease * participated in other drugs and devices studies within 30 days * confirmed as ventricular aneurysm * other conditions not suit for the study after the discussion among the researchers (eg: poor compliance, unable to cooperate for the training)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in inspiratory muscle strength | at baseline, at 30 days | Static maximal inspiratory pressure (MIP) will be selected for the estimation of inspiratory muscle strength. A standard measurement using Powerbreathe® K5 and according to ERS Statement on Respiratory Muscle Testing at Rest and during Exercise published by European Respiratory Society (ERS) will be taken (Laveneziana, 2019). MIP test will be performed at baseline and at 30 days. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pneumonia | up to 30 days | The diagnosis of pneumonia is based on guidelines of the American Thoracic Society \[American Thoracic Society (ATS) and Infectious Diseases Society of America (IDSA), 2005\]. The events of pneumonia will be followed and recorded by experienced doctors when in hospital. After discharged, participants will be followed by the experienced researches, once pneumonia is considered as possible, guidance will be provided for the participants to complete necessary examines, until 30 days. |
| Major adverse cardiovascular events (MACE) | up to 30 days | MACE is defined as: all cause death, recurrence of myocardial infarction, stroke at 30 days. |
| Vital signs of participants during training | up to 30 days | The vital signs of participants during training in hospital will be recorded. |
| Satisfactory assessment | up to 30 days | Satisfaction of the participants in inspiratory muscle training (IMT) group will be evaluated using a questionnaire at the day of discharged and at 30 days. |
| Length of stay | up to 120 days | Length of stay will be assessed by calculating the number of days the patient in the hospital. |
Countries
China
Contacts
Primary ContactYuanhui Liu, MD, PHD
Outcome results
None listed